$CC

CRANSTON MARY B purchased $95K of CC

CRANSTON MARY B purchased 6,000 shares of Chemours Co (CC) at $15.82 on 2026-08-07.

Original reporting
SEC EDGAR · CRANSTON MARY B
Published Aug 11, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

A director’s open-market purchase is a mild positive sentiment input, but the filing alone does not change Chemours’ fundamentals or near-term expectations.

02

Market read

Traders may note the insider buy as a small sentiment signal, but there is no new operational or financial catalyst in the text.

03

What to watch

Insider buys are often less informative without context such as prior trading patterns, option exercises, or concurrent company-specific catalysts.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-11, covering a purchase dated 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Chemours Co (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours Co director Mary B Cranston bought 6,000 shares of CC for about $94,950 on 2026-08-07, disclosed via Form 4 filed 2026-08-11.

Expected impact

Likely limited immediate impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider buys can be read as confidence signals, but the article provides no accompanying guidance, contract, legal, or operational catalyst, and the transaction size is modest relative to typical market-moving events.

Market effects

No sector-level read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase may reflect diversification or personal liquidity needs rather than a forward-looking view, especially since the filing does not include a 10b5-1 plan.

Key entities

  • Chemours Co

    Subject of the Form 4 insider transaction disclosure.

  • CRANSTON MARY B

    Director who purchased 6,000 shares of CC at $15.8250/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCHigh

Why is Chemours stock sliding today?

Chemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.

$CCMed

Mizuho downgrades Chemours stock rating on refrigerants delay

Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.

$CCHigh

Chemours falls as RBC downgrades stock on persistent TiO2 weakness

Chemours Co (CC) shares dropped 2.5% premarket after RBC downgraded it to Sector Perform, citing weak TiO2 demand and reduced growth expectations. RBC cut its price target to $14 from $22 and lowered EBITDA estimates for Q3 and FY26-FY27, citing macro pressures and project delays. The analyst sees limited near-term upside and a fully valued stock at current levels.

$CCMedAI 8/10

Corporations Are Dodging Accountability for PFAS Contamination Around the Globe

Chemours, a chemical company, has been linked to PFAS contamination in the Cape Fear River, North Carolina, affecting drinking water and health. The state reached a $590M settlement with Chemours for damages. PFAS contamination has also been reported near Chemours' facilities worldwide, raising concerns about global environmental and health impacts. Chemours inherited cleanup liabilities from its former parent company, DuPont, after a 2015 spin-off.